NCT01488019View on ClinicalTrials.gov

Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate)

PHASE4CompletedINTERVENTIONAL
Enrollment

1,071

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
COPD
Interventions
DRUG

Perforomist-Placebo

Placebo vehicle, 2mL, twice daily for 52 weeks

DRUG

Perforomist, nebulization, COPD

Perforomist, 20 mcg/2 mL, twice daily for 52 weeks

Trial Locations (1)

29615

Chandar Abboy, Greenville

All Listed Sponsors
lead

Dey

INDUSTRY

NCT01488019 - Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate) | Biotech Hunter | Biotech Hunter